Drug intelligence / Profile preview

bojungikki-tang + atezolizumab

Development stage: Preclinical
Lead developer: Hanpoong Pharm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

Bojungikki-tang + atezolizumab is a combination therapy that pairs a traditional herbal medicine with a modern immunotherapy agent. Bojungikki-tang is a traditional East Asian herbal formula composed of 8-10 medicinal herbs with immunomodulatory and anti-inflammatory properties. Atezolizumab is a PD-L1 inhibitor immunotherapy used in cancer treatment. The combination aims to enhance anti-cancer efficacy by improving immune response while potentially reducing side effects of cancer therapy.

Other names: Bojungikgi-tang + atezolizumabBJIKT + atezolizumabHochu-ekki-to + atezolizumabBu-Zhong-Yi-Qi-Tang + atezolizumab

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on bojungikki-tang + atezolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bojungikki-tang + atezolizumab.

Explore the full profile